NCT00693667View on ClinicalTrials.gov

Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Osteoporosis
Interventions
DRUG

PH3

Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.

Trial Locations (1)

Unknown

Taipei Veteran General Hospital, Taipei

Sponsors
All Listed Sponsors
lead

PhytoHealth Corporation

INDUSTRY